πŸ‡ΊπŸ‡Έ FDA
Patent

US 12097261

CDK2 degraders and uses thereof

granted A61KA61K47/55A61P

Quick answer

US patent 12097261 (CDK2 degraders and uses thereof) held by Kymera Therapeutics, Inc. expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Kymera Therapeutics, Inc.
Grant date
Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K47/55, A61P, A61P35/00